MASTER'S SALE C/A#2022CP4005832 BY VIRTUE of a decree heretofore granted in the case of: Wells Fargo Bank, N.A. vs. Tarina Stone ; Elisabeth Fields ; Any Heirs-at-Law or Devisees of Annie Marie Moore, Deceased, their heirs, Personal Representatives, Administrators, Successors and Assigns, and all other persons entitled to claim through them; all unknown persons with
MASTER'S SALE C/A#2022CP4005832 BY VIRTUE of a decree heretofore granted in the case of: Wells Fargo Bank, N.A. vs. Tarina Stone ; Elisabeth Fields ; Any Heirs-at-Law or Devisees of Annie Marie Moore, Deceased, their heirs, Personal Representatives, Administrators, Successors and Assigns, and all other persons entitled to claim through them; all unknown persons with
MASTER'S SALE C/A#2022CP4005832 BY VIRTUE of a decree heretofore granted in the case of: Wells Fargo Bank, N.A. vs. Tarina Stone ; Elisabeth Fields ; Any Heirs-at-Law or Devisees of Annie Marie Moore, Deceased, their heirs, Personal Representatives, Administrators, Successors and Assigns, and all other persons entitled to claim through them; all unknown persons with
/PRNewswire/ MAPS Public Benefit Corporation (MAPS PBC) today announced the election of Jeff George as the chairman of the board of directors. He replaces.
Wesana Health Closes $4 Million Convertible Note Round
News provided by
Share this article
New additions to senior management and leadership teams
CHICAGO, Jan. 21, 2021 /PRNewswire/ Wesana Health, an emerging life sciences company committed to patient empowerment and the advancement of psilocybin-based medicine to improve health and wellness, has announced the close of a $4 million convertible note financing round. The company also announced new additions to its senior leadership team.
Wesana Health Raises Funds to Enter the Psychedelics Space
The $4 million round, led by The Conscious Fund and Ambria Capital, LLC, provides funding to support the Company s entry into the emerging psychedelics space. The proceeds will allow Wesana to begin preclinical and clinical work on the use of psychedelic-assisted therapy to treat traumatic brain injury (TBI) as well as regulatory applications including Investigational New Drug (IND) filings with the Food and Drug Administration (FDA),